Your browser doesn't support javascript.
loading
HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound.
Offersen, Rasmus; Yu, Wen-Han; Scully, Eileen P; Julg, Boris; Euler, Zelda; Sadanand, Saheli; Garcia-Dominguez, Dario; Zheng, Lu; Rasmussen, Thomas A; Jennewein, Madeleine F; Linde, Caitlyn; Sassic, Jessica; Lofano, Giuseppe; Vigano, Selena; Stephenson, Kathryn E; Fischinger, Stephanie; Suscovich, Todd J; Lichterfeld, Mathias; Lauffenburger, Douglas; Rosenberg, Erik S; Allen, Todd; Altfeld, Marcus; Charles, Richelle C; Østergaard, Lars; Tolstrup, Martin; Barouch, Dan H; Søgaard, Ole S; Alter, Galit.
Afiliación
  • Offersen R; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Infectious Diseases, Aarhus University Hospital, Aarhus 8000, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus 8000, Denmark.
  • Yu WH; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Scully EP; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Julg B; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Euler Z; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Sadanand S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Garcia-Dominguez D; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Zheng L; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Rasmussen TA; Department of Infectious Diseases, Aarhus University Hospital, Aarhus 8000, Denmark.
  • Jennewein MF; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Linde C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Sassic J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Lofano G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Vigano S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Stephenson KE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
  • Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Suscovich TJ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Lichterfeld M; Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Lauffenburger D; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Rosenberg ES; Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Allen T; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Altfeld M; Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.
  • Charles RC; Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Østergaard L; Department of Infectious Diseases, Aarhus University Hospital, Aarhus 8000, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus 8000, Denmark.
  • Tolstrup M; Department of Infectious Diseases, Aarhus University Hospital, Aarhus 8000, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus 8000, Denmark.
  • Barouch DH; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
  • Søgaard OS; Department of Infectious Diseases, Aarhus University Hospital, Aarhus 8000, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus 8000, Denmark.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: galter@mgh.harvard.edu.
Cell Rep ; 33(11): 108502, 2020 12 15.
Article en En | MEDLINE | ID: mdl-33326789
ABSTRACT
Changes in antibody glycosylation are linked to inflammation across several diseases. Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections. However, whether changes in antibody Fc biology also track with reservoir rebound time remains unclear. The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies. Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts. Thus virus-specific antibody glycosylation may represent a promising, simply measured marker to track reservoir reactivation.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Carga Viral Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Cell Rep Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Carga Viral Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Cell Rep Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca